BAY61-3606 affects the viability of colon cancer cells in a genotype-directed manner

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Lau, Ken S ^a,b   Zhang, Tinghu ^c   Kendall, Krystle R ^a   Lauffenburger, Douglas ^b   Gray, Nathanael S ^c   Haigis, Kevin M ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; AZ 628; BAY 61 3606; BAY DERIVATIVE 6; FOSTAMATINIB; GEFITINIB; I KAPPA B KINASE INHIBITOR; I KAPPA B KINASE INHIBITOR VII; IMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; MUTANT PROTEIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE SYK INHIBITOR; RAF PROTEIN; RAF PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL MUTANT; CELL PROLIFERATION; CELL VIABILITY; COLON CANCER; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG SENSITIVITY; ENZYME INHIBITION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; CATALYTIC DOMAIN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SEPARATION; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; GENES, RAS; GENOTYPE; HUMANS; MODELS, GENETIC; MUTATION; NIACINAMIDE; PROTEIN-SERINE-THREONINE KINASES; PYRIMIDINES; RAF KINASES; SIGNAL TRANSDUCTION;

EID: 84863993885     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041343     Document Type: Article

References (39)

1. Malumbres M, Barbacid M, (2003) RAS oncogenes: the first 30 years. Nat Rev Cancer 3: 459-465.
2. Lau KS, Haigis KM, (2009) Non-redundancy within the RAS oncogene family: Insights into mutational disparities in cancer. Mol Cells.
3. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, et al. (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648.
4. Di Fiore F, Blanchard F, Charbonnier F, Le Pessot F, Lamy A, et al. (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 96: 1166-1169.
5. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. The lancet oncology 11: 753-762.
6. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, et al. (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5: 810-816.
7. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, et al. (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439: 358-362.
8. Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, et al. (2008) PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68: 1953-1961.
9. Haigis KM, Kendall KR, Wang Y, Cheung A, Haigis MC, et al. (2008) Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40: 600-608.
10. Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, et al. (2009) Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462: 108-112.
11. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, et al. (2009) Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137: 821-834.
12. Puyol M, Martin A, Dubus P, Mulero F, Pizcueta P, et al. (2010) A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18: 63-73.
13. Luo J, Emanuele MJ, Li D, Creighton CJ, Schlabach MR, et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137: 835-848.
14. Yamamoto N, Takeshita K, Shichijo M, Kokubo T, Sato M, et al. (2003) The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo [1,2-c] pyrimidin-5-ylamino] nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther 306: 1174-1181.
15. Pearce G, Audzevich T, Jessberger R, (2011) SYK regulates B-cell migration by phosphorylation of the F-actin interacting protein SWAP-70. Blood 117: 1574-1584.
16. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, et al. (2004) Cre-lox-regulated conditional RNA interference from transgenes. Proc Natl Acad Sci U S A 101: 10380-10385.
17. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T, (1993) Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260: 85-88.
18. Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, et al. (2008) Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68: 4853-4861.
19. Lyne PD, Aquila B, Cook DJ, Dakin LA, Ezhuthachan J, et al. (2009) Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity. Bioorg Med Chem Lett 19: 1026-1029.
20. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, et al. (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132.
21. Ivanov VN, Kehrl JH, Ronai Z, (2000) Role of TRAF2/GCK in melanoma sensitivity to UV-induced apoptosis. Oncogene 19: 933-942.
22. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954.
23. Wang Y, Van Becelaere K, Jiang P, Przybranowski S, Omer C, et al. (2005) A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. Neoplasia 7: 336-347.
24. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, et al. (2007) Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129: 957-968.
25. Martin TD, Samuel JC, Routh ED, Der CJ, Yeh JJ, (2011) Activation and involvement of Ral GTPases in colorectal cancer. Cancer Res 71: 206-215.
26. Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, et al. (2005) The prevalence of PIK3CA mutations in gastric and colon cancer. European journal of cancer 41: 1649-1654.
27. Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ, (2009) Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. International journal of cancer Journal international du cancer 125: 2332-2341.
28. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, et al. (2009) PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69: 4286-4293.
29. Saikrishnan K, Powell B, Cook NJ, Webb MR, Wigley DB, (2009) Mechanistic basis of 5′-3′ translocation in SF1B helicases. Cell 137: 849-859.
30. Liu Y, Kung C, Fishburn J, Ansari AZ, Shokat KM, et al. (2004) Two cyclin-dependent kinases promote RNA polymerase II transcription and formation of the scaffold complex. Mol Cell Biol 24: 1721-1735.
31. Zhao YC, Kull FJ, Cochran JC, (2010) Modulation of the kinesin ATPase cycle by neck linker docking and microtubule binding. J Biol Chem 285: 25213-25220.
32. Dan I, Watanabe NM, Kusumi A, (2001) The Ste20 group kinases as regulators of MAP kinase cascades. Trends Cell Biol 11: 220-230.
33. Pombo CM, Kehrl JH, Sanchez I, Katz P, Avruch J, et al. (1995) Activation of the SAPK pathway by the human STE20 homologue germinal centre kinase. Nature 377: 750-754.
34. Zhong J, Gavrilescu LC, Molnar A, Murray L, Garafalo S, et al. (2009) GCK is essential to systemic inflammation and pattern recognition receptor signaling to JNK and p38. Proc Natl Acad Sci U S A 106: 4372-4377.
35. Yuasa T, Ohno S, Kehrl JH, Kyriakis JM, (1998) Tumor necrosis factor signaling to stress-activated protein kinase (SAPK)/Jun NH2-terminal kinase (JNK) and p38. Germinal center kinase couples TRAF2 to mitogen-activated protein kinase/ERK kinase kinase 1 and SAPK while receptor interacting protein associates with a mitogen-activated protein kinase kinase kinase upstream of MKK6 and p38. J Biol Chem 273: 22681-22692.
36. Natoli G, Costanzo A, Guido F, Moretti F, Bernardo A, et al. (1998) Nuclear factor kB-independent cytoprotective pathways originating at tumor necrosis factor receptor-associated factor 2. J Biol Chem 273: 31262-31272.
37. Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, et al. (2006) A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 10: 459-472.
38. Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, et al. (2010) Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 70: 8736-8747.
39. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074.